![BAVARIAN NORDIC A/S [CBOE]](/cache/medias/logo_company/150x80-thumb/RBjltVW6VdJzu2q.webp?v=4 "BAVARIAN NORDIC A/S [CBOE]"){kind=logo}
BAVARIAN NORDIC A/S [CBOE] news, videos and press releases
For more news please use our advanced search feature.
BAVARIAN NORDIC A/S [CBOE] - More news...
BAVARIAN NORDIC A/S [CBOE] - More news...
- Bavarian Nordic Announces First Half 2018 Results
- Bavarian Nordic Granted EUR 30 Million Loan from The European Investment Bank
- Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine
- Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer
- Bavarian Nordic A/S - Articles of Association
- Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
- Bavarian Nordic Announces Appointment of Henrik Juuel as Chief Financial Officer
- Bavarian Nordic Announces Interim Results for the First Three Months of 2018
- Bavarian Nordic Receives FDA Orphan Drug Designation for BN-Brachyury for the Treatment of Chordoma
- Bavarian Nordic A/S - Articles of Association
- Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held April 17, 2018
- Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
- Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus
- Bavarian Nordic Awards Restricted Stock Units to Executive Management
- Bavarian Nordic Announces Annual Report 2017
- Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
- Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine
- Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers
- Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine
- Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen
- Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis
- Bavarian Nordic A/S - Articles of Association
- Bavarian Nordic A/S - Articles of Association
- Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
- Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine
- Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
- Bavarian Nordic Announces Interim Results for the First Nine Months of 2017
- Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. Government
- Bavarian Nordic Provides Update on its Universal RSV Vaccine
- Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer
